See the DrugPatentWatch profile for Esperoct
Who Manufactures Esperoct?
Esperoct is manufactured by Novo Nordisk [1].
When Did Novo Nordisk Launch Esperoct?
Novo Nordisk launched Esperoct in the United States in February 2019 [2].
What is Esperoct Used For?
Esperoct is a recombinant factor VIII (rFVIII) therapy used for the routine prophylaxis of bleeding in patients aged 12 years and older with hemophilia A [3]. It is also used for the on-demand treatment of bleeding episodes and for the management of bleeding prior to, during, and after surgical procedures [3].
How is Esperoct Different from Other Hemophilia A Treatments?
Esperoct, also known as turoctocog alfa pegol, is a longer-acting factor VIII replacement therapy. Its prolonged half-life is due to a pegylation process, which allows for less frequent dosing compared to some earlier rFVIII products [3]. This extended duration of action is a key differentiator for patients requiring routine prophylaxis.
When Does Esperoct's Patent Protection End?
Information on the specific patent expiry dates for Esperoct can be found on DrugPatentWatch.com [4]. Drug patent information is complex and can involve multiple patents covering different aspects of a drug, such as its formulation, method of use, or manufacturing process.
What Competition Does Esperoct Face?
Esperoct competes in the hemophilia A market with other recombinant factor VIII products, both standard and long-acting. These include therapies like Advate (albutrecombinant) from Takeda, Xyntha (octocog alfa) from Pfizer, and other extended-half-life products that aim to reduce dosing frequency [5].
What Clinical Data Supports Esperoct's Use?
Clinical trials have evaluated Esperoct's efficacy and safety. For instance, the PROPEL study demonstrated that Esperoct prophylaxis significantly reduced annualized bleeding rates in previously treated boys and men with hemophilia A, with many achieving zero treated bleeds [3].
What are Patient Considerations for Esperoct?
Patients considering Esperoct would typically discuss treatment options with their healthcare providers. Key considerations include the drug's dosing schedule, potential side effects, and the benefits of reduced bleeding frequency. The convenience of a longer-acting prophylactic treatment is often a significant factor for patients with hemophilia A [3].
What is the Regulatory Status of Esperoct?
Esperoct has received marketing authorization from regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for its approved indications [3].
Sources:
1. https://www.novonordisk.com/
2. https://www.outsourcedpharma.com/179421-novo-nordisk-esperoct-approved-for-routine-prophylaxis-of-hemophilia-a/
3. https://www.novocare.com/hemophilia/esperoct.html
4. https://www.drugpatentwatch.com/
5. https://www.hemophilia.org/News-Lounge/Blogs/The-Factor-Blog/2019/New-Extended-Half-Life-Products-for-Hemophilia-A